Haydarpasa Numune Med J. 2021; 61(1): 52-57 | DOI: 10.14744/hnhj.2020.04864

Ýlaca Dirençli Fokal Epilepsisi Olan Çocuklarda Lakozamid’in Etkinliði

Canan Yýldýrým¹, Yeþim Coþkun^2
1Okan Üniversitesi Týp Fakültesi, Çocuk Saðlýðý ve Hastalýklarý Anabilim Dalý, Çocuk Nörolojisi Bilim Dalý, Ýstanbul
²Koç Üniversitesi Hastanesi, Çocuk Saðlýðý ve Hastalýklarý Anabilim Dalý, Ýstanbul

GÝRÝÞ ve AMAÇ: Bu çalýþmada direkçli fokal epilepsisi olan çocuklarda Lakozamid (LCM) tedavisinin etkinliði, tolere edilebilirliði ve yan etkilerinin araþtýrýlmasý amaçlanmýþtýr.
YÖNTEM ve GEREÇLER: Ýlaca dirençli fokal epilepsisi olan16 yaþýndan küçük çocuklar çalýþmaya dahil edildi. Üç ayda bir týbbi kayýtlar ve nöbet günlükleri incelendi. LCM’ye yanýt nöbet sýklýðýnda ≥50% azalma olarak tanýmlandý.
BULGULAR: Ýlaca dirençli fokal epilepsisi olan 25 çocuðun tedavisine LCM eklendi. Ortalama epilepsi süresi 5.2 yýl ve LCM baþlama yaþý ortalama 8 yaþtý. LCM tedavisine yanýt oraný 3., 6. ve 9. aylarda sýrasýyla %44, %64, %76 idi. Onikinci ayýn sonunda cevap oraný %84 idi ve hastalarýn %16’sýnda nöbet yoktu. Dört hastada yan etki geliþti; üç hastada LCM tedavisi sonlandýrýldý ve bir hastada doz azaltýldýðýnda yan etki düzeldi.
TARTIÞMA ve SONUÇ: LCM, dirençli fokal epilepsisi olan çocuklar için etkili bir antiepileptik ilaçtýr. Nöbet sýklýðýný zamanla azaltýr. Ýyi tolere edilir ve bu hastalarda umut verici bir seçenektir.

Anahtar Kelimeler: Çocuk, fokal epilepsi, ilaca dirençi epilepsi, lakozamid

---

The Efficacy of Lacosamide in Children with Drug-resistant Focal Epilepsy

Canan Yýldýrým¹, Yeþim Coþkun^2
1Department of Pediatrics, Division of Pediatric Neurology, Okan University Faculty of Medicine, Istanbul, Turkey
²Department of Pediatrics, Koc University Hospital, Istanbul, Turkey

INTRODUCTION: This study aimed to assess the efficacy, tolerability and adverse effects of Lacosamide (LCM) in children with refractory focal epilepsy.
METHODS: Children aged younger than 16 years with drug-resistant focal epilepsy were enrolled. The medical records and seizure diaries that were evaluated every three months were reviewed. Response to LCM was defined as ≥50% reduction in seizure frequency.
RESULTS: Twenty-five children with drug-resistant focal epilepsy received LCM as add-on therapy. The mean duration of epilepsy was 5.2 years and the mean age at LCM initiation was 8 years. The rate of response to LCM treatment in the 3th, 6th and 9th months were 44%, 64%, 76%, respectively. At the end of 12 months, the response rate was 84% and 16% of the patients were seizure free. Four patients had adverse effects; three patients were discontinued LCM and one improved after decreasing the dose of the drug.
DISCUSSION AND CONCLUSION: LCM is an effective add-on antiepileptic drug for children with refractory focal epilepsy. It diminishes the frequency of seizures over time. It is well tolerated and a promising option in these patients.

Keywords: Children, drug-resistant epilepsy; focal epilepsy; lacosamide.

---

ATIF KOPYALA